COLLEEN ANN SWEENEY

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint EGF receptor activation by heterologous mechanisms
    Kermit L Carraway
    University of California, Davis, Cancer Center, Sacramento 95817, USA
    Cancer Cell 1:405-6. 2002
  2. pmc The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells
    Heather C Workman
    Division of Basic Sciences, UC Davis Cancer Center, 4645 2ndAvenue, Sacramento, California 95817, USA
    Breast Cancer Res 11:R70. 2009
  3. ncbi request reprint Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors
    C Sweeney
    Department of Cell Biology, Harvard Medical School and Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Biol Chem 276:22685-98. 2001
  4. ncbi request reprint ErbB receptor negative regulatory mechanisms: implications in cancer
    Colleen Sweeney
    UC Davis Cancer Center, Research Bldg III, rm 1400, 4645 2nd Avenue, Sacramento, CA 95817, USA
    J Mammary Gland Biol Neoplasia 11:89-99. 2006
  5. pmc Negative regulation of ErbB family receptor tyrosine kinases
    C Sweeney
    UC Davis Cancer Center, University of California, Research Building III, Room 1400, 4645 2nd Avenue, Davis, Sacramento CA 95817, USA
    Br J Cancer 90:289-93. 2004
  6. ncbi request reprint Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth
    Lily Yen
    University of California Davis Cancer Center, Sacramento, CA 95817 2305, USA
    Cancer Res 66:11279-86. 2006
  7. ncbi request reprint The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3
    Melanie Funes
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    J Biol Chem 281:19310-9. 2006
  8. doi request reprint Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
    David L Shattuck
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Cancer Res 68:1471-7. 2008
  9. pmc Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors
    Ellen Q Ingalla
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    J Biol Chem 285:28691-7. 2010
  10. pmc Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells
    Imran H Khan
    Center for Comparative Medicine, University of California at Davis, Hutchison Drive and County Road 98, Davis, CA 95616, USA
    Assay Drug Dev Technol 8:27-36. 2010

Research Grants

  1. Mechanisms of Receptor Tyrosine Kinase Inhibition
    COLLEEN ANN SWEENEY; Fiscal Year: 2010
  2. Mechanisms of Receptor Tyrosine Kinase Inhibition
    COLLEEN ANN SWEENEY; Fiscal Year: 2010

Collaborators

Detail Information

Publications23

  1. ncbi request reprint EGF receptor activation by heterologous mechanisms
    Kermit L Carraway
    University of California, Davis, Cancer Center, Sacramento 95817, USA
    Cancer Cell 1:405-6. 2002
    ..A myriad of growth factor-dependent and -independent mechanisms for activating the EGF receptor and the related ErbB receptors underscore the importance of receptor inhibitors in the treatment of some solid tumors...
  2. pmc The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells
    Heather C Workman
    Division of Basic Sciences, UC Davis Cancer Center, 4645 2ndAvenue, Sacramento, California 95817, USA
    Breast Cancer Res 11:R70. 2009
    ....
  3. ncbi request reprint Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors
    C Sweeney
    Department of Cell Biology, Harvard Medical School and Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Biol Chem 276:22685-98. 2001
    ..Our observations also suggest that the identity and kinetics of signaling pathway usage by RTKs may play a role in the selection of regulated genes...
  4. ncbi request reprint ErbB receptor negative regulatory mechanisms: implications in cancer
    Colleen Sweeney
    UC Davis Cancer Center, Research Bldg III, rm 1400, 4645 2nd Avenue, Sacramento, CA 95817, USA
    J Mammary Gland Biol Neoplasia 11:89-99. 2006
    ..Here we will discuss several proteins that directly interact with ErbB receptors to suppress signaling, highlighting the potential impact of their loss on tumor progression...
  5. pmc Negative regulation of ErbB family receptor tyrosine kinases
    C Sweeney
    UC Davis Cancer Center, University of California, Research Building III, Room 1400, 4645 2nd Avenue, Davis, Sacramento CA 95817, USA
    Br J Cancer 90:289-93. 2004
    ....
  6. ncbi request reprint Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth
    Lily Yen
    University of California Davis Cancer Center, Sacramento, CA 95817 2305, USA
    Cancer Res 66:11279-86. 2006
    ..Our observations suggest that Nrdp1-mediated ErbB3 degradation suppresses cellular growth and motility, and that Nrdp1 loss in breast tumors may promote tumor progression by augmenting ErbB2/ErbB3 signaling...
  7. ncbi request reprint The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3
    Melanie Funes
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    J Biol Chem 281:19310-9. 2006
    ....
  8. doi request reprint Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
    David L Shattuck
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Cancer Res 68:1471-7. 2008
    ..Our study suggests that a subset of Her2 (+) patients may benefit from combined inhibition of Her2 and Met...
  9. pmc Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors
    Ellen Q Ingalla
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    J Biol Chem 285:28691-7. 2010
    ..These observations indicate that mammary tumors use potent post-transcriptional mechanisms to suppress Nrdp1 protein levels and that protein destabilization may play a central role in Nrdp1 loss in tumors...
  10. pmc Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells
    Imran H Khan
    Center for Comparative Medicine, University of California at Davis, Hutchison Drive and County Road 98, Davis, CA 95616, USA
    Assay Drug Dev Technol 8:27-36. 2010
    ..In addition, the assays described here may be useful for cancer diagnostics and monitoring efficacy of therapy targeting the ErbB family of RTKs...
  11. ncbi request reprint Co-opted integrin signaling in ErbB2-induced mammary tumor progression
    Kermit L Carraway
    University of California, Davis, Cancer Center, Sacramento, California 95817, USA
    Cancer Cell 10:93-5. 2006
    ..These observations offer novel mechanistic insight into ErbB2 action and highlight the notion that ErbB2 co-opts the functions of other signaling proteins to elicit tumor progression...
  12. pmc Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer
    Jamie K Miller
    School of Medicine, Davis Cancer Center, University of California at Davis, Sacramento, California 95817, USA
    Cancer Res 68:8286-94. 2008
    ..Moreover, our observations point to the existence of a feed-forward regulatory loop in breast tumor cells where aberrant ErbB2 signaling suppresses LRIG1 protein levels, which in turn contributes to ErbB2 overexpression...
  13. pmc LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy
    David L Shattuck
    UC Davis Cancer Center, Research Building III, Room 1400, 4645 2nd Ave, Sacramento, CA 95817, USA
    Mol Cell Biol 27:1934-46. 2007
    ..We conclude that LRIG1 is a novel suppressor of Met function, serving to regulate cellular receptor levels by promoting Met degradation in a ligand- and cbl-independent manner...
  14. ncbi request reprint Epidermal growth factor receptor activation under oxidative stress fails to promote c-Cbl mediated down-regulation
    Tommer Ravid
    Signal Transduction, Department of Internal Medicine, Cancer Center, University of California School of Medicine, Davis, CA 95616, USA
    J Biol Chem 277:31214-9. 2002
    ..In summary, H(2)O(2) stimulation results in an activated receptor uncoupled from normal down-regulation, a process that may contribute to oxidant-mediated tumorigenesis...
  15. ncbi request reprint The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases
    Melanie B Laederich
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    J Biol Chem 279:47050-6. 2004
    ....
  16. pmc Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1
    Zhongwei Cao
    UC Davis Cancer Center, Sacramento, CA 95817, USA
    Mol Cell Biol 27:2180-8. 2007
    ..Our observations raise the possibility that the ligand-induced augmentation of pathways involved in the maintenance of basal levels of receptor tyrosine kinases can contribute to ligand-stimulated down-regulation...
  17. pmc An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels
    A John Diamonti
    Department of Cell Biology, Harvard Medical School and Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Proc Natl Acad Sci U S A 99:2866-71. 2002
    ..Our observations suggest that Nrdp1 may act to regulate steady-state cell surface neuregulin receptor levels, thereby influencing the efficiency of neuregulin signaling...
  18. pmc The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms
    Heather C Workman
    UC Davis Cancer Center, Sacramento, California 95817, USA
    Cancer Res 69:2845-52. 2009
    ....
  19. pmc Mechanisms of ErbB receptor negative regulation and relevance in cancer
    William H D Fry
    UC Davis Cancer Center, Research Building III, Rm 1100B, 4645 2nd Avenue, Sacramento, California 95817, USA
    Exp Cell Res 315:697-706. 2009
    ....
  20. ncbi request reprint Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways
    Kermit L Carraway
    UC Davis Cancer Center, Sacramento, California 95817, USA
    Curr Top Dev Biol 78:1-22. 2007
    ..We also discuss how tumor cells exploit these mechanisms to promote their own growth and metastasis...
  21. pmc Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERĪ±-positive breast cancer
    Sheryl R Krig
    Division of Basic Sciences, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Mol Cancer Res 9:1406-17. 2011
    ..This work provides strong evidence for a growth-inhibitory role for Lrig1 in breast cancer...
  22. doi request reprint Isolating the effects of social interactions on cancer biology
    Brian C Trainor
    Department of Pathology and Laboratory Medicine, School of Medicine, 2795 Second Street, University of California Davis, Davis, CA 95616, USA
    Cancer Prev Res (Phila) 2:843-6. 2009
    ..Our growing understanding of the actions of glucocorticoids on breast tumors could lead to important changes in cancer treatment...
  23. pmc Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8
    Xiuli Wu
    UC Davis Cancer Center, Research Building III, Room 1400, 4645 2nd Ave, Sacramento, CA 95817, USA
    Mol Cell Biol 24:7748-57. 2004
    ..Our results indicate that Nrdp1 is a specific target for the USP8 deubiquitinating enzyme and are consistent with a model where USP8 augments Nrdp1 activity by mediating its stabilization...

Research Grants7

  1. Mechanisms of Receptor Tyrosine Kinase Inhibition
    COLLEEN ANN SWEENEY; Fiscal Year: 2010
    ..The proposed project will lay the biochemical foundation for LRIG1 as a negative regulator of ErbB receptor function. ..
  2. Mechanisms of Receptor Tyrosine Kinase Inhibition
    COLLEEN ANN SWEENEY; Fiscal Year: 2010
    ..The proposed project will lay the biochemical foundation for LRIG1 as a negative regulator of ErbB receptor function. ..